1. Ferguson NM, Cummings DA, Fraser C, et al. Strategies for mitigating an influenza pandemic. Nature. 2006;442(7101):448–52.
2. Koszalka P, Tilmanis D, Hurt AC. Influenza antivirals currently in late-phase clinical trial. Influenza Other Respir Viruses. 2017;11(3):240–6.
3. Shionogi & Co. Ltd. XofluxaTM (baloxavir): Japanese prescribing information 2018.
http://www.pmda.go.jp/
. Accessed 26 Feb 2018.
4. Shionogi & Co. Ltd. XofluzaTM (baloxavir marboxil) tablets 10 mg/20 mg approved for the treatment of influenza types A and B in Japan [media release]. 23 Feb 2018.
5. Shionogi & Co. Ltd. Shionogi enters into a license and collaboration agreement with Roche for its anti-flu drug, S-033188 [media release]. 29 Feb 2016.